TCGA-E2-A14W-01A-11R-A12D-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 32
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.400
- MTORC1_SIGNALING+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.390
- MYC_TARGETS_V1+0.380
- OXIDATIVE_PHOSPHORYLATION+0.380
- PROTEIN_SECRETION+0.380
- E2F_TARGETS+0.260
- GLYCOLYSIS+0.260
- PEROXISOME+0.220
- G2M_CHECKPOINT+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- HEDGEHOG_SIGNALING-0.520
- ALLOGRAFT_REJECTION-0.510
- INTERFERON_GAMMA_RESPONSE-0.510
- WNT_BETA_CATENIN_SIGNALING-0.480
- IL6_JAK_STAT3_SIGNALING-0.450
- INFLAMMATORY_RESPONSE-0.420
- KRAS_SIGNALING_UP-0.410
- APICAL_SURFACE-0.400
- COMPLEMENT-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AG12-TTM1-A-1-1-R-A743-41 | — | C | 0.909 |
| 2 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.906 |
| 3 | BSR_20_0054redo_S62 | — | B | 0.897 |
| 4 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.897 |
| 5 | 4e2a5058-c190-49de-97f4-0ba7be7ebfe8 | — | — | 0.896 |
| 6 | ULC0410T_S45 | — | cohortA4 | 0.890 |
| 7 | SRR2016943 | — | — | 0.890 |
| 8 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.887 |
| 9 | TCGA-AR-A0TY-01A-12R-A115-07 | — | B | 0.884 |
| 10 | SRR8518448 | — | C | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |